Is Eli Lilly Stock A Buy After Slashing The Price Of Its New Weight-Loss Drug?

Blockhead09-13

Eli Lilly (LLY) stock hit an intraday record high on Aug. 22. The company recently said its weight-loss drug lowered the risk of developing diabetes by 94%. ↑ X How Novo Nordisk, Wegovy And ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467701734?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt-150x150.jpg","is_english":true,"pubTime":"2024-09-13 01:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467701734","market":"us","top_or_hot":-1,"title":"Is Eli Lilly Stock A Buy After Slashing The Price Of Its New Weight-Loss Drug?","media":"Blockhead","content":"<div>\n<p>Eli Lilly (LLY) stock hit an intraday record high on Aug. 22. The company recently said its weight-loss drug lowered the risk of developing diabetes by 94%.\n\n\n\n↑\nX\n\n\n\n\nHow Novo Nordisk, Wegovy And ...</p>\n\n<a href=\"https://www.investors.com/news/technology/eli-lilly-stock-buy-now/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Eli Lilly Stock A Buy After Slashing The Price Of Its New Weight-Loss Drug?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Eli Lilly Stock A Buy After Slashing The Price Of Its New Weight-Loss Drug?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-13 01:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/eli-lilly-stock-buy-now/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly (LLY) stock hit an intraday record high on Aug. 22. The company recently said its weight-loss drug lowered the risk of developing diabetes by 94%.\n\n\n\n↑\nX\n\n\n\n\nHow Novo Nordisk, Wegovy And ...</p>\n\n<a href=\"https://www.investors.com/news/technology/eli-lilly-stock-buy-now/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://www.investors.com/news/technology/eli-lilly-stock-buy-now/","article_id":"2467701734","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467701734","pubTimestamp":1726161462,"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Eli Lilly halved the price of a new version of its weight-loss drug, Zepbound. Is Eli Lilly stock a buy right now?","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","NVO.AU":"NOVO RESOURCES CORP-CDI","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BIIB":"渤健公司","LU0058720904.USD":"联博国际健康护理基金A","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","BK4007":"制药","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","INCY":"因塞特医疗","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","NVO":"诺和诺德","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LLY":"礼来","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","ESAIY":"Eisai Co., Ltd.","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4585":"ETF&股票定投概念","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4516":"特朗普概念"},"translate_title":"礼来公司减肥药新药降价后值得买入吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"NVO.AU":1,"ESAIY":1,"NVO":1,"LLY":1,"INCY":1},"content_text":"Eli Lilly (LLY) stock hit an intraday record high on Aug. 22. The company recently said its weight-loss drug lowered the risk of developing diabetes by 94%.\n\n\n\n↑\nX\n\n\n\n\nHow Novo Nordisk, Wegovy And Ozempic Are Changing The Weight-Loss Game For Patients And Investors\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow Novo Nordisk, Wegovy And Ozempic Are Changing The Weight-Loss Game For Patients And Investors\n\n\n\n\nAfter three years, patients with prediabetes and obesity who took Lilly's tirzepatide had a 94% lower risk of developing type 2 diabetes. Patients also lost an average 22.9% of their body weight vs. just 2.1% weight loss for the placebo group.\nThe company also announced on Aug. 27 a lower-cost version of the same drug for weight loss. Single-dose vials of Zepbound will be available at least 50% below the list price of all other similar treatments for obesity.\nOn Sept. 4, Lilly unveiled an agreement with Eva Pharma to expand access to Olumiant, a treatment for inflammatory conditions. Incyte (INCY) discovered the drug and licensed it to Lilly.\nNotably, Eli Lilly also knocked its second-quarter earnings out of the park. Its diabetes and weight-loss drugs Mounjaro and Zepbound — both forms of tirzepatide — beat expectations by $973 million. And Lilly hiked its sales outlook for the year by $3 billion.\nThe company also just wrapped its acquisition of Morphic Holding for $3.2 billion. The Morphic deal centers on the company's lead asset, an experimental treatment for ulcerative colitis and Crohn's disease. Further, Lilly announced Sept. 9 the appointment of Lucas Montarce as chief financial officer.\nSo, is Lilly stock a buy or a sell right now?\nEli Lilly Stock: Bullish Sales Growth\nIn the second quarter, Eli Lilly earned an adjusted $3.92 per share on $11.3 billion in sales. Earnings skyrocketed 86% and crushed forecasts for $2.74 a share, according to FactSet. Sales advanced 36% and came in north of expectations for $9.97 billion.\nMounjaro and Zepbound both topped views, though diabetes treatment Trulicity came in light at $1.25 billion and fell 31%. Similarly, sales of another diabetes med, Jardiance, missed forecasts.\nPromisingly, sales of breast cancer drug Verzenio, beat expectations and grew 28% to $1.33 billion.\nFor the third quarter, analysts expect $4.49 earnings per share and $12.22 billion in sales. Earnings would rocket by a quadruple-digit percentage as sales grow about 29%.\nAfter the second-quarter report, Eli Lilly guided to $45.4 billion to $46.6 billion in 2024 sales. Lilly plans to bolster its production of diabetes and weight-loss drugs later this year. The company also calls for adjusted earnings of $15.10 to $15.60 per share. Both measures topped analysts' forecasts.\nEli Lilly Stock Analysis\nEli Lilly stock isn't currently forming a base. But shares are above their 50-day and 200-day moving averages.\nShares have a strong Relative Strength Rating of 92 out of a best-possible 99, IBD Digital shows. This puts shares in the top 8% of all stocks when it comes to 12-month performance. Lilly stock also has a perfect Composite Rating of 99, a measure of fundamental and technical metrics.\nRecent News Around Lilly Stock\nThe race to develop new weight-loss drugs continues to heat up.\nLilly stock fell in July after Pfizer and Viking announced plans to run additional testing for obesity treatments. Roche's test results also pressured Lilly shares.\nFurther, Eli Lilly stock fell after President Joe Biden and Sen. Bernie Sanders criticized the prices it and Novo Nordisk (NVO) charge for their obesity treatments, Zepbound and Wegovy.\nLilly is also working on a next-generation weekly shot called retatrutide. While tirzepatide loops in two hormonal targets to stoke weight loss, retatrutide targets three. Its oral weight-loss drug, dubbed orforglipron, is also expected to be the first weight-loss pill to hit the market.\nIn other news, Lilly's Alzheimer's drug, donanemab, gained Food and Drug Administration approval in July. It will sell under the brand name Kisunla.\nKisunla works by removing a built-up protein called beta amyloid. In testing, Kisunla worked better in patients whose amyloid included a protein called tau. Across all patients, donanemab slowed cognitive decline by 22% to 29% over 18 months. In patients with intermediate levels of tau, donanemab slowed the decline by 35% to 36%.\nIt rivals Biogen (BIIB) and Eisai's (ESAIY) Leqembi.\nIs LLY Stock A Buy Or A Sell Right Now?\nEli Lilly stock is neither a buy nor a sell. Shares retook their 50-day line on Aug. 9 — a bullish sign. But the stock isn't forming a base for investors to watch.\nPromisingly, Lilly reported strong second-quarter sales and earnings growth that beat expectations.\nIt will be key to watch how the markets for weight-loss drugs and Alzheimer's treatments unfold.\nTo find the best stocks to buy and watch, check out IBD Stock Lists. Make sure to also keep tabs on stocks to buy or sell.\nFollow Allison Gatlin on Twitter at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nIs Moderna Stock A Buy After Unexpectedly Raising Its 2023 Sales Outlook?\nIs Pfizer Stock A Buy Or A Sell With Covid-Era Growth In The Rearview?\nWatch IBD's Investing Strategies Show For Actionable Market Insights\nGet Timely Buy & Sell Alerts With IBD Leaderboard\nBest Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467701734"}